Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Santidrian AF et al
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
Originally FDA-approved as Ozempic for type 2 diabetes in 2017, semaglutide was subsequently approved as Wegovy for chronic weight management in 2021 making it one of the most rigorously studied weight loss medications ever approved
People who have struggled with weight are finally finding relief in the form of a painless weekly injection
US$ 20.98
US$ 25.54
US$ 27.34
US$ 21.30
US$ 20.92
US$ 22.86
